<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03018691</url>
  </required_header>
  <id_info>
    <org_study_id>271-102-00002</org_study_id>
    <secondary_id>JapicCTI-173484</secondary_id>
    <nct_id>NCT03018691</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Trial to Assess the Safety and Efficacy of 0.3% and 1% OPA-15406 Ointments When Administered for 4 Weeks in Pediatric Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1%
      OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects experiencing AEs</measure>
    <time_frame>Week 0-4</time_frame>
    <description>The number of subjects experiencing AEs will be calculated for each treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of subjects experiencing AEs</measure>
    <time_frame>Week 0-4</time_frame>
    <description>The percentage of subjects experiencing AEs will be calculated for each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA) response rate at week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Incidence of success in IGA at Week 4: percentage of subjects with an IGA score of 0 or 1 with an improvement by at least 2 grades (responders)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of OPA-15406</measure>
    <time_frame>Week 1 and Week 4</time_frame>
    <description>The plasma concentration of OPA-15406 will be measured at Week 1 and Week 4. On the day of measurement, the subjects will visit the trial site without morning Investigational Medicinal Product (IMP) administration.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>0.3% OPA-15406 Ointments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% OPA-15406 Ointments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were treated with assigned 1% OPA-15406 ointment twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Ointments</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects were treated with assigned 0% OPA-15406 ointment twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPA-15406</intervention_name>
    <arm_group_label>0.3% OPA-15406 Ointments</arm_group_label>
    <arm_group_label>1% OPA-15406 Ointments</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo Ointments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka

        Exclusion Criteria:

          -  Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a
             sudden intensification of atopic dermatitis.

          -  Subjects who have an active viral skin infection.

          -  Subjects with a current or history of malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

